Active Biotech’s business strategy is to develop and commercialize proprietary products through strategic partnerships. Active Biotech is currently seeking business partners to secure the continued development of tasquinimod for treatment of multiple myeloma, paquinimod for systemic sclerosis and the pre-clinical SILC project within the oncology field.
Current collaborations include partnerships with Teva Pharmaceutical Industries Ltd. for development of laquinimod in neurodegenerative diseases and NeoTX Therapeutics Ltd. for development of ANYARA in cancer.
NeoTX Therapeutics Ltd.
On October 26, 2016 – Active Biotech announced an agreement with NeoTX Therapeutics Ltd., for the development and commercialization of Naptumomab estafenatox “ANYARA” for cancer immunotherapy.
The licensing agreement grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech received USD 250,000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.
Teva Pharmaceutical Industries Ltd.
On June 14, 2004 – Active Biotech signed an agreement with Teva Pharmaceutical Industries Ltd., to develop and commercialize laquinimod worldwide.
Teva provided an upfront payment of USD 5 million to Active Biotech and it is conducting and funding the further clinical development of laquinimod. The contract between the two companies also calls for Teva to make payments to Active Biotech upon the achievement of various milestones, which include sales targets. If such milestones were all to be met, payments to Active Biotech would aggregate to USD 92 million. Active Biotech will also receive tiered double-digit royalties on sales of the product, once marketed.